The Washington Post is providing this important information about the coronavirus for free. For more free coverage of the coronavirus pandemic, sign up for our Coronavirus Updates newsletter where all stories are free to read.
U.S. health officials lifted a temporary pause on the use of the Johnson & Johnson coronavirus vaccine shortly after an expert panel recommended that vaccinations resume for all adults amid concerns about a rare risk of blood clots.
The decision, announced Friday by the Food and Drug Administration and the Centers for Disease Control and Prevention, came hours after the CDC’s Advisory Committee on Immunization Practices advised that the single-shot vaccine include a label that warns people to seek medical attention if they develop worrying symptoms. Several European nations and South Africa either resumed the shot’s use or began distributing doses, following a finding by Europe’s drug regulator that the vaccine’s benefits outweighed the possible risks.
- Pregnant women confused by conflicting recommendations on coronavirus vaccination over the past few months now have clear guidance from the CDC: Get the shots.
- The Johnson & Johnson pause has delayed vaccinations for some hard-to-reach people and forced some health-care providers to switch to the more cumbersome Moderna and Pfizer-BioNTech products. That is complicating the next big push in the U.S. vaccination effort, which involves reaching out to people experiencing homelessness and others who have trouble accessing vaccines.
- Amid a huge surge in coronavirus cases in India, countries around the world are restricting travel from the South Asian giant in a move that recalls some of the earliest days of the pandemic.
- Researchers are working to understand more about vaccines’ effectiveness within the immunocompromised community. Here’s what patients with compromised immune systems need to know.
- Japan declared a state of emergency covering Tokyo and three western prefectures Friday, moving to curb a surge in infections attributed to more-contagious variants.
- A single dose of the Pfizer-BioNTech or AstraZeneca coronavirus vaccine sharply reduced the risk of infection in all age groups, researchers at Oxford University, which co-developed the AstraZeneca shot, said in a new study.
- The European Union plans to initiate legal action against British-Swedish vaccine-maker AstraZeneca after the company failed to supply the tens of millions of doses it had pledged to deliver in a contract with the bloc.
- More than 570,000 people have died of covid-19 in the United States, out of some 31.9 million infections. New cases have dropped 12 percent over the past week, but public health experts worry that an ambitious vaccination drive is slowing ahead of the herd-immunity threshold.